At the recent Revolutionizing Atopic Dermatitis (RAD) conference, Dr. Linda Stein Gold, Director of Dermatology Clinical Research and Division Head of Dermatology at Henry Ford Health, presented pivotal data from the “Level Up” study—a head-to-head comparison of two advanced treatments for atopic dermatitis: Rinvoq and Dupixent. This study, conducted by AbbVie, sheds new light on therapeutic options for managing this challenging condition.

In an exclusive interview with JDD, Dr. Stein Gold delves deeper into the findings presented at RAD, offering valuable insights into how the “Level Up” study could influence treatment decisions moving forward. The conversation explores not only the data but also the potential implications for patient care, helping dermatologists navigate the evolving landscape of
treatment strategies.

Watch the full interview with Dr. Stein Gold as she shares her expert perspective on the “Level Up” study and what it means for patients and physicians alike.